Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

IMPORTANCE: There is a strong rationale for treating sarcomas with immunotherapy. OBJECTIVE: To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, multi...

詳細記述

保存先:
書誌詳細
出版年:JAMA Oncol
主要な著者: Toulmonde, Maud, Penel, Nicolas, Adam, Julien, Chevreau, Christine, Blay, Jean-Yves, Le Cesne, Axel, Bompas, Emmanuelle, Piperno-Neumann, Sophie, Cousin, Sophie, Grellety, Thomas, Ryckewaert, Thomas, Bessede, Alban, Ghiringhelli, François, Pulido, Marina, Italiano, Antoine
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2017
主題:
Brief Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833654/
https://ncbi.nlm.nih.gov/pubmed/28662235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1617
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料